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Labeling of Antibodies
for Immuno-Positron Emission Tomography
Malay Patra,1,2 Simon Klingler,1 Larissa S. Eichenberger,1 and Jason P. Holland1,3,*
SUMMARY
A method for the simultaneous (one-step) photochemical conjugation and 89Zr-radiolabeling of anti-
bodies is introduced. A photoactivatable chelate based on the functionalization of desferrioxamine
B with an arylazide moiety (DFO-ArN3, [1]) was synthesized. The radiolabeled complex,
89Zr-1+, was
produced and characterized. Density functional theory calculations were used to investigate the
mechanism of arylazide photoactivation. 89Zr-radiolabeling experiments were also used to determine
the efficiency of photochemical conjugation. A standard two-step approach gave ameasured conjuga-
tion efficiency of 3.5% G 0.4%. In contrast, the one-step process gave a higher photoradiolabeling
efficiency of 76%. Stability measurements, cellular saturation binding assays, positron emission
tomographic imaging, and biodistribution studies in mice bearing SK-OV-3 tumors confirmed the
biochemical viability and tumor specificity of photoradiolabeled [89Zr]ZrDFO-azepin-trastuzumab.
Experimental data support the conclusion that the combination of photochemistry and radiochemistry
is a viable strategy for producing radiolabeled proteins for imaging and therapy.
INTRODUCTION
The use of photochemically activated compounds for labeling proteins and other biologically active mol-
ecules was introduced by Westheimer and co-workers in 1962 (Singh et al., 1962). Since then, photoaffinity
labeling (PAL) has matured, and a wide array of reagents are available for studying the structure and func-
tion of biological systems (Bayley and Knowles, 1977; Chowdhry and Westheimer, 1979; Kotzyba-Hilbert
et al., 1995). Photochemical activation offers a number of advantages over thermochemical processes.
For instance, photoreactive groups can be selected whereby, (1) the reagent is stable under ambient con-
ditions, (2) photoactivation occurs specifically at a wavelength that is not absorbed by the biological vector,
and (3) the conjugation step involves a chemoselective reaction with the target molecule. Furthermore,
because photochemical activation proceeds via an excited electronic state that generates extremely reac-
tive intermediates like carbenes, nitrenes, and radicals, the rates of photochemical conjugation reactions
can be several orders of magnitude faster than those of standardmethods (Dennler et al., 2015; Gritsan and
Platz, 2006; Kla´n and Wirz, 2009; Platz, 1995). High reactivity of the photo-induced intermediates presents
both advantages and disadvantages. One of the benefits is that photoactive reagents can yield high label-
ing efficiencies in short reaction times. However, to achieve efficient conjugation, PAL methods often rely
on a mechanism in which the photoactive reagent and the target protein form a non-covalent pre-associ-
ation complex. Pre-association facilitates pseudo-first-order intramolecular bond formation and minimizes
the probability of quenching by background media (i.e., by the solvent, oxygen, salts, etc.). However, the
problem with this approach is that it restricts most PAL tools to systems that self-assemble.
From the radiochemistry perspective, photochemical reactions are an attractive platform for developing
radiotracers. For molecules that undergo radioactive decay, chemical kinetics is one of the main factors
in determining if a reaction is suitable for use in radiotracer synthesis (Holland, 2018). As photochemical
reactions often proceed with rate constants that tend toward the rate of diffusion, combining photochem-
istry with radiochemistry (photoradiochemistry) is a logical step.
Several groups have reported the use of photochemical reactions in the synthesis of radiolabeled com-
pounds (Hashizume et al., 1995; Kumar et al., 2015; Kym et al., 1995; Lange et al., 2002; Nishikawa et al.,
2003; Pandurangi et al., 1997a, 1997c; 1997b, 1998; Rajagopalan et al., 2002; Stalteri and Mather, 1996;
Sykes et al., 1995, 1997; Wester et al., 1996). However, it is surprising that to date, photochemistry has
had minimal impact on radiopharmaceutical science. The main bottlenecks to a more widespread use of
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photoradiochemistry for labeling proteins, peptides, and small molecules are (1) avoiding the need to form
a pre-associated complex, (2) controlling chemoselectivity in the presence of competing nucleophiles, and
(3) ensuring that the rate of productive bimolecular conjugation exceeds that of background quenching
reactions. If a photochemical process can be tuned to favor bimolecular coupling, then photoradiochem-
istry may become a more general tool in radiotracer synthesis.
A specific area for potential applications of photoradiochemistry is the synthesis of radiolabeled mono-
clonal antibodies (mAbs) or immunoglobulin fragments for use in positron emission tomography (im-
muno-PET) and radioimmunotherapy (Boros and Holland, 2018). Zirconium-89 (t1/2 = 78.41 h) has emerged
as the radionuclide of choice for immuno-PET. In almost all available methods for radiolabeling mAbs, the
production of 89Zr-mAbs relies on a two-step procedure (Scheme 1). Initially, the antibody is purified from a
source and then functionalized with a suitable metal-ion-binding chelate. For 89Zr, the chelate of choice is
usually a derivative of desferrioxamine B (DFO), but a number of alternative chelates have been reported
(Boros and Holland, 2018). After conjugation, the functionalized mAb is re-purified, characterized, and
stored before radiolabeling. Although this two-step approach is highly successful, there are several draw-
backs. First, the conjugation chemistry is time consuming and may involve multiple chemical transforma-
tions that risk compromising the biological integrity of the mAb. Second, for applications in the clinic,
Scheme 1. Mechanistic Routes toward Radiolabeled Antibodies and Other Proteins
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the conjugation chemistry should ideally be performed in accordance with current Good Manufacturing
Practice. Third, the conjugated mAb is a new molecular entity, which may be subject to stringent testing,
including expensive toxicological test. Finally, storage of the radiolabeling precursor raises concerns over
the long-term chemical and biochemical stability.
We postulated that photoradiochemistry could be used to streamline the production of radiolabeledmAbs
(and other radiolabeled proteins or peptides) by simplifying the procedure to a one-pot reaction and elim-
inating the need to isolate or store the functionalized intermediate. Two mechanistically distinct processes
can be envisaged for a one-pot procedure: a two-step pre-radiolabeling approach and a one-step pathway
in which the radiolabeling and photochemical conjugation reactions occur simultaneously. Here, we
present detailed experimental and theoretical data evaluating the photoradiochemical synthesis of
89Zr-labeled trastuzumab.
RESULTS AND DISCUSSION
Our initial proof-of-concept studies found that themacrocyclic chelate, (2-(4,7-bis(carboxymethyl)-1,4,7-tri-
azonan-1-yl)pentanedioic acid (NODAGA), when functionalized with a photoreactive arylazide (ArN3) facil-
itated a two-step photoradiolabeling of trastuzumab with 68Ga3+ ions (Eichenberger et al., 2019; Patra
et al., 2019). Although technically feasible, the combination of short-lived 68Ga (t1/2 = 67.71 min) with
mAbs (150 kDa) is not ideal because of the mismatch between the timescales of radioactive decay and
radiotracer pharmacokinetics in vivo. In addition, 68Ga3+ radiochemistry usually requires acidic media (to
avoid hydrolysis of themetal ion), which is suboptimal for photochemical conjugation using the ArN3 group
(Borden et al., 2000; Gritsan and Platz, 2010, 2006; Gritsan and Pritchina, 1992). Here, we focused our efforts
on developing a photoradiochemical process for producing 89Zr-labeled mAbs. Zirconium-89 radiochem-
istry normally starts from the zirconium tetraoxalate anion, [89Zr][Zr(C2O4)4]
4–(aq.), and complexation by
DFO derivatives can be accomplished over a wide pH range (from approximately pH 5–10, with optimal
yields attained by using pH 6–8.5) (Holland and Vasdev, 2014; Vosjan et al., 2010). Thus 89Zr-radiochemistry
is not only ideal for immuno-PET but also facilitates simultaneous photoradiolabeling.
Chemical and Radiochemical Synthesis
Thephotoactive chelateDFO-ArN3 (1) was synthesizedbyusingstandardchemical transformations (Scheme2).
The compound was isolated in high purity by semi-preparative high-performance liquid chromatography and
characterized by ultrahigh-performance liquid chromatography (UHPLC), high-resolution electrospray ioniza-
tionmass spectrometry (HR-ESI-MS), one- and two-dimensional 1H and 13C nuclear magnetic resonance spec-
troscopies, and electronic absorption spectroscopy (Transparent Methods Figures S2–S8).
The non-radioactive complex, [ZrDFO-ArN3]
+ (Zr-1+), was prepared by the reaction of compound 1 with
ZrCl4(aq.), and characterized by HR-ESI-MS and UHPLC (Figure 1 and Transparent Methods Figures S9
and S10). The radiolabeled complex [89Zr][ZrDFO-ArN3]
+ (89Zr-1+) was prepared as a single radioactive
species, the identity of which was confirmed by comparison of retention times with the authenticated
non-radioactive sample and by standard co-injection methods (Figure 1, blue radiotrace).
Photochemical Kinetics
After confirming that 89Zr-1+ could be prepared via standard radiolabeling methods, the photochemical
activity of compound 1 was tested under irradiation with UV light. Three separate light sources were tested
including two variable-intensity light-emitting diodes (LEDs) with peak emission wavelengths at 365 nm
and 395 nm and a high-powered Rayonet reactor (Transparent Methods Figure S1). The photochemical
degradation kinetics of compound 1, induced by using variable light intensities, was monitored by UHPLC
(Figure 2 and Transparent Methods Table S2). Experiments confirmed that compound 1 was photoactive.
All peaks in the UHPLC associated with photodegraded products were found to be more hydrophilic than
the parent compound, which is consistent with the established mechanism of ArN3 activation in aqueous
media (Kla´n and Wirz, 2009). After light absorption, ArN3 releases N2(g) and forms a short-lived arylnitrene
species in the singlet (1A2) ground state (Gritsan and Platz, 2006). This arylnitrene undergoes rapid intramo-
lecular rearrangement to give benzazirine or ketenimine intermediates (Platz, 1995). When powerful nucle-
ophiles are present, the ketenimine species reacts to form more polar azepine adducts. In the absence of
nucleophiles, hydrolysis reactions can form the 3H-azepin-2-ol or the 1,3-dihydro-2H-azepin-2-one tauto-
mers (Bou-Hamdan et al., 2011). Photo-irradiated samples of compound 1 showed that at least six new
418 iScience 13, 416–431, March 29, 2019
species formed (Figure 2A). This observation is consistent with the mechanism of activation. The DFO
ligand contains several nucleophilic groups (hydroxamates) that can induce intramolecular reactions
with the ketenimine intermediate forming various cycles.
By integrating the peak in the UHPLC associated with compound 1, it was possible to measure the photo-
chemical degradation kinetics (Figure 2B). At room temperature, and using the LED (365 nm) at different
intensities (25%, 50%, and 100%), the photochemical degradation of compound 1 fitted a first-order kinetic
scheme (non-linear regression coefficient, R2 >0.999 at each light intensity). Changes in the observed rate
constant, kobs/min
1, were found to be linearly dependent on the light intensity (Figure 2C). These data are
consistent with the anticipated photochemical response of molecules containing ArN3 groups (Gritsan and
Platz, 2006; Gritsan and Pritchina, 1992; Kla´n and Wirz, 2009).
Quantum Yield of Photochemical Activation
How efficient is photochemical activation of the ArN3 in compound 1? This question can be answered by
determining the photochemical quantum yield (F), which is defined as the ratio of the number of reactions
(nr) to the number of photons absorbed (nabs, Equation 1) (Kla´n and Wirz, 2009)
Figure 1. Radioactive UHPLC Characterization Data
UHPLC chromatograms showing quantitative radiolabeling to give
[89Zr][ZrDFO-ArN3]
+ (89Zr-1+, blue trace, RCP >99%, RCC >99%) and
electronic absorption chromatograms measured at 220 nm (green),
254 nm (red), and 280 nm (black) showing co-elution with an
authenticated sample of non-radioactive Zr-1+.
Scheme 2. Chemical Synthesis of DFO-ArN3 (1) and Complexation of Zr
4+ Ions to Give the Non-radioactive (Zr-1+) and Radiolabeled 89Zr-1+)
Coordination Complexes
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F=
nr
nabs
(Equation 1)
An expression for the number of reactions at time t is given by the change in concentration (c) of the starting
material multiplied by the volume (V, Equation 2).
nrðtÞ= ðc0  cðtÞÞ$V (Equation 2)
The molar photon flux q0m;g is defined as the number of photons in moles (i.e., in units of Einstein) incident
on a sample per unit time and can be expressed as the light power (P0m;g) divided by the product of
Avogadro’s constant (NA) and the energy of each photon (hn) as given by Equation 3.
q0m;g =
P0m;g
NA$hn
(Equation 3)
The fraction of photons absorbed can be expressed as 1 minus the transmittance (T), which can be
substituted for the measured absorbance using the Beer-Lambert law (Equation 4).
TðtÞ= 10AðtÞ; where AðtÞ= 3l cðtÞ d (Equation 4)
The differential photon absorption (dngðtÞ) at a given time and wavelength (l) can be calculated by
Equation 5.
dnabsðtÞ=q0m;l

1 10AðtÞdt (Equation 5)
Finally, it follows that the quantum yield is given by Equation 6.
F=
ðc0  cðtÞÞ$VR t
0 q
0
m;l½1 10AðtÞdt
(Equation 6)
Using experimental values from the kinetics of photochemical degradation of compound 1, a photochem-
ical quantum yield of 4.35%G 0.43% was calculated. This means that around one in every23 photons that
is absorbed (at365 nm) leads to photochemical activation via loss of N2 as opposed to relaxation through
other radiative or non-radiative (chemical quenching) pathways. These data indicated that photochemical
activation of compound 1, and other molecules functionalized with the ArN3 group, is a highly efficient
process.
Density Functional Theory Calculations
Next, to understand the thermochemical stability and photochemical reactivity of compound 1 in more
detail, density functional theory (DFT) calculations were performed. The acyclic nature of compound 1
means that the compound has a large degree of conformational freedom. Therefore, to simplify calculation
of the reaction coordinate and the electronic excitation profile, the non-substituted arylazide (benzylazide)
was used as a model compound. All calculations used the uB3LYP/6-311++G(d,p) level of theory and
included a polarizable continuum model (PCM, water). The calculated reaction coordinate is shown in
Figure 2. Kinetic Data on the Photochemically Induced Degradation of Compound 1 during Irradiation with UV
Light (365 nm)
(A) Normalized UHPLC chromatograms recorded between 0 and 25 min (50% LED power). * Indicates starting material
(compound 1).
(B) Kinetic plot showing the change in concentration of compound 1 versus irradiation time (min.) using different LED
intensities. Note, data are fitted with a first-order decay (R2 >0.999 for each dataset), and the observed first-order rate
constants, kobs/min
1, are shown in the inset. Error bars correspond to one standard deviation.
(C) Plot of the normalized observed rate constant versus the normalized LED intensity confirming that photodegradation
is first order (gradient 1.0) with respect to light intensity.
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Figure 3. Relative changes in the reaction free energy, DG; enthalpy, DH; and entropy DS of each species,
including all transition states between the arylazide starting material and the most stable geometric isomer
formed (cis-N-methyl-3H-azepin-2-amine) after addition of methylamine to the ketenimine intermediate,
are shown. In addition, relative energies of the possible electronic states of the arylnitrene were calculated.
The first feature to note is that formation of transition state 1 (TS1), which corresponds to loss of N2 from
arylazide, has a calculated free energy barrier of 143 kJ mol1 in solution phase. This high barrier accounts
for the thermal stability of the ArN3 group and contributes to the prolonged shelf-life of chelates (like com-
pound 1) that are derivatized with ArN3. Irradiation with UV light can circumvent this thermodynamic barrier
(see the time-dependent DFT [TD-DFT)] section below) and leads to the formation of arylnitrene in the
lowest energy open-shell singlet state (1A2). The
1A2 ground state has a formal electronic configuration
of (px)
1(py)
1 where the two unpaired electrons are primarily located in the p-orbitals of the nitrogen
atom with some delocalization to the aromatic ring. Formation of the more stable triplet state (3A2) is
spin forbidden, and the two closed-shell singlet states (both 1A1 with either (px)
2 or (py)
2 electronic config-
urations centered on the N atom) are calculated to be higher in energy, with a low probability of populating
these states at ambient temperature. The TS2 corresponding to the intramolecular rearrangement of aryl-
nitrene has a calculated barrier of onlyDDGTS2 = 54 kJmol
1, which includes destabilization from the loss of
aromaticity. After ring insertion occurs, the benzazirine species (DG = 22 kJ mol1) isomerizes to give the
more stable ketenimine intermediate (DG =3 kJ mol1) via a relatively low-energy TS3 (DG = 37 kJ mol1).
Nucleophilic attack by methylamine (CH3NH2) at the 2-position of the ketenimine intermediate
proceeds via TS4 (DG = 51 kJ mol1) and initially produces the NH-azepin adduct. This NH-azepin then
isomerizes to yield the cis-azepin-2-amine product. Formation of the azepin-2-amine from benzylazide
and methylamine is calculated to be thermodynamically spontaneous with an overall reaction free energy
of DG =166 kJ mol1. As expected, the main driving force for the initial photoactivation is entropic (N2(g)
release, DS = +137 J1 K1 mol1). However, nucleophilic addition to the ketenimine, and similarly, conju-
gation of a photoactive chelate to a biologically active molecule, is driven primarily by changes in enthalpy
(DH = 173 kJ mol1).
Figure 3. DFT-Calculated (uB3LYP/6-311++G(d,p)/PCM) Reaction Coordinate
The relative calculated differences in free energy (DG/kJ mol1), enthalpy (DH/kJ mol1), and entropy (DS/J K1 mol1, at
298.15 K) of the various intermediates and transition states that connect arylazide (PhN3) with the N-methyl-cis-azepin-2-
amine product are shown. Photochemically induced reactivity of arylazides proceeds via the ground-state open-shell
singlet nitrene (1A2 state) corresponding to the (px)
1(py)
1 electronic configuration where the py orbital on the N atom lies in
the plane of the C6H5 ring. Note, owing to spin contamination, the energy of the
1A2 state was estimated using the sum
method by Ziegler et al. (Ziegler and Rank, 1977).
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TD-DFT calculations were used to probe the electronic nature of the photoactivation of arylazide. An over-
lay of the experimentally measured electronic absorption spectrum of compound 1 (in MeOH) and the
TD-DFT-calculated spectrum is presented in Figure 4 (see also Transparent Methods Figure S8 and
Table S1). Perhaps surprisingly, compound 1, and indeed arylazide compounds like 4-azidobenzoic acid
show almost no absorbance at wavelengths above 325 nm. Measurements of the molar absorption coef-
ficients at 365 and 395 nm gave values of 16.9G 1.9 M1 cm1 and 5.2G 1.3 M1 cm1, respectively. Never-
theless, TD-DFT calculations of the 16 lowest energy excited states (including both singlets and triplets) of
arylazide confirmed that excitation bands are present in the wavelength range used to promote the photo-
chemistry. Electronic transitions to six major singlet excited states (assigned as bands A to F) contribute to
the measured absorption profile of compound 1 in the region 200–600 nm. Note that at shorter wave-
lengths, the fit between the calculated and the experimental spectrum is less accurate because of the
use of the model arylazide and the continuum solvation model, which do not account for the full electronic
complexity or solvation dynamics of compound 1. However, experimental features associated with absorp-
tion at wavelengths >250 nm are well reproduced.
TD-DFT calculations allow deconvolution of the change in the electronic density associated with the forma-
tion of a particular excited state in terms of electronic mixing between the ground-state molecular orbitals
(MOs) (Figure 5, and Transparent Methods Table S1). MO analysis from TD-DFT calculations performed on
benzylazide found that absorption band A (corresponding to excitation to the lowest energy excited
singlet state) involves 96.4% mixing of the electron density from the highest occupied MO to the lowest
unoccupied molecular orbital (LUMO). Inspection of the MO isosurfaces showed that this transition in-
volves primarily transfer of electron density from a populated pp* orbital of the benzyl ring to the unoccu-
pied, in-plane antibonding pp* orbital centered on the azide group. Populating this excited state weakens
the azide bond and stimulates N2 dissociation. Interestingly, our experimental observations indicate that
any wavelength that populates the first excited singlet state can induce arylazide activation. However,
test experiments using a shorter-wavelength LED (275 nm), which populates the second or third excited
singlet states (bands B and C, respectively), found negligible photochemical activation of the ArN3 group
(data not shown). This observation is consistent with the TD-DFT calculations, which indicate that bands
B and C involve electronic transitions to higher-energy virtual orbitals (LUMO+1 and above). Kasha’s
rule suggests that relaxation of second and third excited singlet states of ArN3 should populate the
LUMO, but inspection of the MOs shows that this process is symmetry forbidden (Figure 5).
Two-Step Photochemical Conjugation and 89Zr-Radiolabeling of Trastuzumab
Before investigating a simultaneous one-pot photoradiochemical process, experiments were performed
using the traditional two-step approach. This route involved the photochemical conjugation between com-
pound 1 and trastuzumab, followed by 89Zr-radiolabeling (Scheme 3, bottom pathway). The photochemical
Figure 4. Experimental Electronic Absorption Spectroscopy and Time-Dependent DFT
Overlay of the experimentally measured electronic absorption spectrum of compound 1 and the TD-DFT (uB3LYP/
6-311++G(d,p)/PCM)-calculated spectrum of the model compound arylazide (PhN3). Note that the calculated spectrum
was produced by using Lorentzian broadening, 20-nm full-width at half maximum. Calculated energies and oscillator
strengths (f/a.u.) of the bands corresponding to transitions to the first six excited singlet states with non-zero expectation
values are shown by vertical red lines (band details inset). For reference, band energies to the excited triplet states are
shown by vertical green lines. The simulated spectrum and all calculated energies are x-shifted by +12 nm for clarity.
Molecular orbital contributions involved in the excitation to the main singlet bands are presented in Table S1.
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conjugation was performed at room temperature for 25 min using a Rayonet reactor. The DFO-azepin-tras-
tuzumab conjugate was purified by using a combination of size exclusion chromatography (SEC) methods
including spin column centrifugation and preparative PD-10 gel filtration. DFO-azepin-trastuzumab was
then radiolabeled with 89Zr using standard conditions (Holland et al., 2010b, 2010a; 2012; Rylova et al.,
2016; Verel et al., 2003a, 2003b; Vosjan et al., 2010). Aliquots of the crude radiolabeling mixture were re-
tained, and then the product was purified and formulated in sterile PBS by using standard SEC methods.
Analytical measurements on the crude and purified samples of [89Zr]ZrDFO-azepin-trastuzumab were per-
formed using radioactive instant thin-layer chromatography (radio-iTLC), analytical PD-10-SEC, and radio-
active SEC-UHPLC (Figure 6).
Experiments confirmed that the DFO-azepin-trastuzumab was radiolabeled efficiently with 89Zr giving a
crude radiochemical conversion (RCC) of >98% after incubating the mixture at room temperature for
15 min. On scaling up the radiolabeling reaction for use in cellular and animal experiments, the final radio-
chemical yield (RCY) of the purified sample was >99%, and the radiochemical purity (RCP) was measured
at >99.5% by analytical PD-10-SEC and >98% by SEC-UHPLC. For the preparations used in the animal
studies, the final activity concentration was 29.7 MBq mL1, with a decay-corrected molar activity (Am) of
13.7 MBq nmol1 of protein for the stock sample used in the normal doses (vide infra).
Further 89Zr-radiolabeling experiments were performed to measure the radiolabeling kinetics and overall
RCC yields of DFO-azepin-trastuzumab samples that were prepared using different initial chelate-to-mAb
ratios in the photochemical conjugation step (Figure 7 and Transparent Methods Figure S11). For each
sample, the radiolabeling kinetics was monitored by radio-iTLC (Figure 7A) and the RCC (%) versus time
was plotted (Figure 7B). These experiments showed a linear relation between the initial chelate-to-mAb
ratio and the overall RCC at equilibrium (time points >60 min, Figure S11). Using these data, combined
with the experimentally determined molar activity of the stock solution of [89Zr][Zr(C2O4)4]
4– (measured
by titration with DFO) (Rylova et al., 2016) the photochemical conjugation efficiency between DFO-ArN3
(1) and trastuzumab was estimated to be 3.5%G 0.4% (n = 3). Hence, for the samples used in the biological
Figure 5. Molecular Orbital Diagram of ArN3
DFT-calculated (B3LYP/6-311++G(d,p)/PCM) molecular orbital diagram. Electron density isosurfaces of the three highest
occupiedmolecular orbitals (HOMOs) and three lowest unoccupiedmolecular orbitals (LUMOs) for the model compound
arylazide (PhN3) are shown. Note that the isosurfaces were generated by using a contour value of 0.035 and correspond to
96.5% of the total electron density.
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studies, an initial chelate-to-mAb ratio of 26.4:1 yielded 0.85 accessible chelates per mAb in the final
product.
The radiochemical stability of [89Zr]ZrDFO-azepin-trastuzumab with respect to change in the RCP during
incubation in human serum at 37 C for up to 92 h was determined by SEC-UHPLC (Figure 7C). Experiments
confirmed that the 89Zr activity remained bound to the mAb (<2% decrease in RCP after 92 h) with essen-
tially no transchelation serum proteins (transferrin, albumin, etc.).
Cellular Saturation Binding Assays (Immunoreactivity)
The biochemical viability of [89Zr]ZrDFO-azepin-trastuzumab wasmeasured by using standard cellular satu-
ration binding assays in accordance with the methods introduced by Lindmo et al.(Junghans, 1999; Konishi
Figure 6. Characterization Data for the Radiochemical Synthesis of [89Zr]ZrDFO-Azepin-Trastuzumab
(A) Radio-iTLC chromatograms showing [89Zr]ZrEDTA control; the crude reaction mixture at 15, 40, and 60 min; and the
purified product.
(B and C) (B) Analytical PD-10-SEC elution profiles, and (C) SEC-UHPLC chromatograms of the crude and purified product.
Scheme 3. Photoradiochemical Synthesis of [89Zr]ZrDFO-Azepin-Trastuzumab via Three Separate Routes
(Top) Pre-radiolabelling and subsequent photochemical conjugation of [89Zr]ZrDFO-ArN3 (
89Zr-1+) with the antibody. (Middle) Simultaneous one-step
photoradiochemical labeling. (Bottom) Two-step photochemical conjugation of the antibody and subsequent 89Zr radiolabeling of the isolated
DFO-azepin-trastuzumab intermediate.
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et al., 2004; Lindmo et al., 1984). The human ovarian cancer cell line SK-OV-3 shows high expression of the
human epidermal growth factor receptor 2 (HER2/neu), which is the target protein of trastuzumab. Satura-
tion binding experiments confirmed that the protein remained biochemically active with an estimated
immunoreactivity fraction between 63% and 74% (n = 2, Figure 8). Note that these cellular assays were incu-
bated for only 1 h and the slightly low value of the immunoreactivity is primarily associated with slow bind-
ing kinetics. Nevertheless, the immunoreactive fraction is comparable to the reported value of 87%G 7%
obtained with [89Zr]ZrDFO-Nsucc-trastuzumab that was conjugated using one of the standard thermo-
chemical routes (N-succinyl activated ester) (Holland et al., 2010a).
Small-Animal PET Imaging and Biodistribution Studies
After confirming that [89Zr]ZrDFO-azepin-trastuzumab was chemically stable and biochemically active
in vitro, the pharmacokinetics and target specificity were evaluated in athymic nude mice bearing subcu-
taneous SK-OV-3 tumors. PET images were recorded at multiple time points between 2 and 94 h post-
administration. Two groups of mice were used. The normal group (n = 5) received a high molar activity
formulation (13.7 MBq nmol1), and the blocking group received the same amount of radioactivity but a
reduced molar activity of 0.14 MBq nmol1. Representative PET images showing coronal and axial planes
taken through the center of the tumors are presented in Figure 9 (see also Transparent Methods Figures
S12 and S13). PET imaging data were also quantified by drawing volumes-of-interest over various tissues
and plotting the data as time-activity bar charts (Figure 10, based on quantification of the images in units
of percentage injected dose per gram (%ID g1), and Figure S14 for equivalent data using image quanti-
fication in units of the mean standardized uptake value). The pharmacokinetic profile and tumor uptake of
[89Zr]ZrDFO-azepin-trastuzumab was consistent with previously reported experiments using 89Zr-DFO-
radiolabeled trastuzumab produced via traditional coupling chemistries (Holland et al., 2010a).
Figure 7. [89Zr]ZrDFO-azepin-trastuzumab Radiolabeling Kinetics and Stability Data
(A) Radio-iTLC chromatograms showing the kinetics of formation of [89Zr]ZrDFO-azepin-trastuzumab versus time using a
pre-functionalized DFO-azepin-trastuzumab sample prepared with an initial chelate-to-mAb ratio of 26.4:1. Data for
reactions starting with different initial chelate-to-mAb ratios are presented in Figure S11.
(B) Plot of the percentage radiochemical conversion (RCC) versus time using samples of DFO-azepin-trastuzumab pre-
conjugated at different initial chelate-to-mAb ratios.
(C) Radioactive SEC-UHPLC confirming that [89Zr]ZrDFO-azepin-trastuzumab remains stable with respect to change in
radiochemical purity during incubation in human serum at 37 C for 92 h.
Figure 8. Measurement of the Immunoreactive Fraction of [89Zr]ZrDFO-Azepin-Trastuzumab as Determined by
Cellular Binding to SK-OV-3 (HER2/neu positive) Cells
(A) Saturation binding plot. Error bars correspond to one standard deviation.
(B) Lindmo plot.
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The effective half-life (t1/2(eff)/h) of [
89Zr]ZrDFO-azepin-trastuzumab was measured in mice by using a
calibrated dosimeter (Transparent Methods Figure S15). A value of t1/2(eff) = 45.7 G 7.7 h was measured
(n = 11; R2  0.99) with an estimated biological half-life, t1/2(biol.) = 109.5 G 18.4 h. No difference was
observed between the normal and blocking groups. These data are consistent with previous reports on
89Zr-radiolabeled trastuzumab (Dijkers et al., 2009; Holland et al., 2010a).
After the final imaging time point, animals were euthanized and a biodistribution analysis was performed to
obtain accurate quantification of the accumulation of 89Zr in different tissues (Figure 11, Table 1 and Trans-
parent Methods Figures S16–S19). Comparison of the biodistribution data between the normal and block-
ing groups showed a specific accumulation of radioactivity in the tumor (65.8% G 14.2 %ID g1 in the
normal group versus 12.1% G 4.1%ID g1 in the blocking group, p value = 0.0006). With the exception
of the activity retained in the blood pool (7.4% G 1.0 %ID g1 for the normal versus 4.8% G 1.2 %ID g1
for the blocking group [p value = 0.003]), no statistically significant differences were observed between
radioactivity accumulation in the background tissues of the two groups of mice. Furthermore, a comparison
of the tumor-to-tissue contrast ratios recorded from the biodistribution studies performed on the photo-
radiochemical product [89Zr]ZrDFO-azepin-trastuzumab and on [89Zr]ZrDFO-Nsucc-trastuzumab produced
by a conventional conjugation route showed no statistically significant differences between the two radio-
tracers (Transparent Methods Figure S20).(Holland et al., 2010a) Collectively, the data from experiments
performed in vitro, in vivo, and ex vivo indicate that the photoradiochemical route to 89Zr-radiolabeled tras-
tuzumab yields a radiolabeled compound that is of equivalent quality to other 89Zr-mAbs produced via
established methods.
Simultaneous Photoradiolabeling of Trastuzumab
Previously, we demonstrated that the photoradiochemical approach was successful when radiolabeling
either pre-purified mAbs or fully formulated samples (Herceptin) (Patra et al., 2019). In addition to fast
reaction and processing times, a one-pot procedure has the unique advantage of avoiding the need to
isolate and characterize the conjugated intermediate antibodies. To illustrate the feasibility of the simulta-
neous photoradiochemical process, experiments were performed to produce [89Zr]ZrDFO-azepin-trastu-
zumab in a single step.
Reactions were established in which [89Zr][Zr(C2O4)4]
4–, compound 1, and trastuzumab (at an initial chelate-to-
mAb ratio of29:1) weremixed in water and the pH adjusted to8–9. Control reactions were performed in the
absence of either the chelate (1) or the mAb. Mixtures were stirred gently at room temperature and irradiated
using the LED source (365 or 395 nm) for 10 min. Note that in this case stirring appeared to be more important
than in our previous experiments with 68Ga (Patra et al., 2019). After irradiation, the reactions were quenched by
Figure 9. Temporal [89Zr]ZrDFO-Azepin-Trastuzumab PET Images Recorded in Mice Bearing SK-OV-3 Tumors on the Right Flank
T, tumor; H, heart; L, liver; Sp, spleen
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the addition of diethylenetriamine pentaacetic acid (DTPA). Aliquots of the crude samples were retained, and a
fraction was purified by SEC methods. Crude and purified samples were then analyzed by using radio-iTLC,
analytical PD-10-SEC, and SEC-UHPLC methods (Figure 12 and Transparent Methods Table S3).
Analysis of the crude reaction mixtures also indicated that 72%–73% (n = 2, by analytical PD-10-SEC) and
67%–88% (n = 2, by SEC-UHPLC) of the 89Zr-radioactivity was associated with trastuzumab. Control reac-
tions confirmed that the 89Zr radioactivity bound to trastuzumab specifically (Figures 12A and 12B, green
and yellow traces). After purification, simultaneous photoradiolabeling gave [89Zr]ZrDFO-azepin-trastuzu-
mab with a decay-corrected RCY of 76%, a RCP 97% (measured by SEC-UHPLC), and a molar activity of
0.41 MBq nmol1 of protein (n = 2). Interestingly, both the 365- and 395-nm LED sources gave equivalent
radiochemical conversions. Reactions were complete in <10 min, and the entire process, from non-labeled
trastuzumab to formulated [89Zr]ZrDFO-azepin-trastuzumab, was accomplished in <15 min. With a higher
intensity light source, it is conceivable that the photoradiochemical synthesis could be accomplished in a
few seconds, which would mean that radiotracer production times are limited only by the time required for
purification and quality control.
Comparison of the final RCYs measured between the two-step process and the simultaneous (one-step)
process indicate that the photochemical conjugation efficiency increased from 3.5% to 76%. This result
Figure 10. Time-Activity Bar Chart Showing the Activity Associated with Different Tissues (volumes of Interest,
VOI) versus Time
Data presented are based on quantification of the PET images in units of %ID cm3. Equivalent data using quantification
of the PET images in terms of the mean standardized uptake value are shown in Figure S14. Error bars correspond to one
standard deviation.
Figure 11. Bar Chart Showing Ex Vivo Biodistribution Data (%ID/g) for the Uptake of [89Zr]ZrDFO-Azepin-
Trastuzumab in Mice Bearing Subcutaneous SK-OV-3 Tumors
Data were recorded after the final imaging time point at 94 h post-injection. ***Student’s t test p value < 0.001. An
equivalent plot using units of standardized uptake value is presented in Figure S17. Data showing tumor-to-tissue
contrast ratios are presented in Figure S18. Error bars correspond to one standard deviation.
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shows that the chemical efficiency of simultaneous photoradiolabeling is comparable to many of the most
efficient thermally mediated methods, which typically display 60%–80% conjugation efficiency (Holland
et al., 2010b, 2010a; 2012; Rylova et al., 2016; Verel et al., 2003a, 2003b; Vosjan et al., 2010). Under the con-
ditions employed it is likely that the kinetics of metal ion complexation is equal to, or faster than, that of the
photochemical conjugation step. Complexation of 89Zr4+ ions by the DFO-ArN3 chelate reduces the prob-
ability of intramolecular reactions between the nucleophilic hydroxamate groups and the photo-generated
intermediates. Hence, pre-complexation increases the photochemical conjugation efficiency when
compared with the free chelate (1). Notably, the photoradiochemical method is also suitable for use in fully
automated radiochemical synthesis modules. Automated photoradiochemical synthesis has the potential
to change the way in which radiolabeled mAbs, immunoglobulin fragments, and other proteins are pro-
duced in the clinic.
Conclusions
Experiments demonstrated that the photoradiolabeling methods are viable for the synthesis of
radiolabeled antibodies for immuno-PET. In contrast to existing (thermochemical) technologies,
photoradiochemistry allows for the rapid synthesis of [89Zr]ZrDFO-azepin-trastuzumab in high radio-
chemical yield and purity using a simultaneous, one-pot approach. Accessing radiolabeled proteins
directly from the non-functionalized source eliminates the need to isolate and characterize a radio-
labeling precursor (here DFO-azepin-trastuzumab). Our work illustrates the potential of applying
photochemistry in radiopharmaceutical science. We continue to investigate the use of photoradio-
chemistry with different photoactivatable groups, chelates, and radionuclides for producing
Tissue Normal Group (n = 5) Blocking Group
(n = 6)
[89Zr]ZrDFO-Azepin-
Trastuzumab (94 h)/%
ID g1G SDa
Tumor-to-Tissue
Contrast RatioG SDb
[89Zr]ZrDFO-
Azepin-Trastuzumab
(94 h)/%ID g1 G SDa
Tumour-to-
Tissue Contrast
RatioG SDb
Blood 7.36G 0.96 8.94G 2.25 4.79G 1.18 2.53G 1.05
Tumor 65.79G 14.19 1.00 12.10G 4.06 1.00
Heart 2.58G 0.49 25.51G 7.32 2.22G 0.28 5.45G 1.95
Lungs 4.22G 0.75 15.57G 4.35 3.17G 0.60 3.82G 1.47
Liver 9.90G 1.44 6.64G 1.73 7.99G 2.56 1.51G 0.70
Spleen 5.28G 1.24 12.45G 3.97 5.64G 1.48 2.14G 0.91
Stomach 0.79G 0.15 83.03G 23.85 0.74G 0.19 16.36G 6.95
Pancreas 1.39G 0.28 47.27G 13.91 0.98G 0.10 12.39G 4.37
Kidney 4.16G 0.57 15.82G 4.03 3.35G 0.50 3.61G 1.33
Small
intestine
1.28G 0.28 51.30G 15.70 1.33G 0.28 9.13G 3.62
Large
intestine
0.74G 0.20 88.79G 30.95 0.79G 0.17 15.29G 6.10
Fat 2.22G 1.29 29.61G 18.31 0.78G 0.32 15.49G 8.24
Muscle 0.82G 0.30 79.84G 33.39 0.71G 0.12 17.05G 6.39
Bone 9.86G 2.29 6.67G 2.12 5.85G 4.24 2.07G 1.65
Skin 4.51G 0.73 14.58G 3.94 4.09G 0.86 2.96G 1.17
Table 1. Ex Vivo Biodistribution Data for [89Zr]ZrDFO-Azepin-Trastuzumab in Mice Bearing SK-OV-3 Tumors
aUptake data are expressed as the mean %ID g1 G one standard deviation (SD).
bErrors for the tumor-to-tissue ratios are calculated as the geometric mean of the standard deviations.
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diagnostic and therapeutic radiopharmaceuticals based on proteins, peptides, small molecules, and
nanoparticles.
Limitations of the Study
Although photoradiochemistry offers an exciting alternative for the synthesis of radiolabeled proteins, and
we have shown that photoradiochemistry can facilitate processes that are not achievable using standard
thermochemical methods, some limitations exist. Namely, the success of the photoradiochemical reaction
is dependent on the experimental geometry. The light-activation process was found to be highly efficient,
but experimentally, the shape and focus point of the light beam, the photon flux, and the potential absorp-
tion or scattering from the reaction vessel or chemical components of the reaction mixture mean that care
must be taken to achieve reproducible results. Similar to standard thermochemical methods, we have also
discovered that the photochemical conjugation efficiency depends on the nature of the photoactive group,
the chelate or complex, and also other factors including the protein, solvent composition, mixing efficiency,
and concentration-dependent radiochemical kinetics (Holland, 2018). Much work is required before photo-
radiochemical methods can be standardized.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
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Transparent methods 
General details 
 
Unless otherwise stated, all chemicals were of reagent grade and purchased from SigmaAldrich (St. Louis, MO), 
Merck (Darmstadt, Germany), Tokyo Chemical Industry (Eschborn, Germany), abcr (Karlsruhe, Germany) or 
CheMatech (Dijon, France). Water (>18.2 MΩ·cm at 25 ºC, Puranity TU 3 UV/UF, VWR International, Leuven, 
Belgium) was used without further purification. Solvents for reactions were of reagent grade, and where necessary, 
were dried over molecular sieves. Evaporation of the solvents was performed under reduced pressure by using a 
rotary evaporator (Rotavapor R-300, Büchi Labortechnik AG, Flawil, Switzerland) at the specified temperature and 
pressure. 
 
1H and 13C NMR spectra were measured in deuterated solvents on a Bruker AV-400 (1H: 400 MHz, 13C: 100.6 MHz) 
or a Bruker AV-500 (1H: 500 MHz, 13C: 125.8 MHz) spectrometer. Chemical shifts (d) are expressed in parts per 
million (ppm) relative to the resonance of the residual solvent peaks, for example, with DMSO dH = 2.50 ppm and dC = 
39.5 ppm with respect to tetramethylsilane (TMS, dH and dC = 0.00 ppm). Coupling constants (J) are reported in Hz. 
All resonances were assigned by using a combination of 1D and 2D NMR (HSQC, COSY) spectra. Peak multiplicities 
are abbreviated as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet), and br 
(broad). 
 
High-resolution electrospray ionisation mass spectra (HR-ESI-MS) were measured by the mass spectrometry service 
at the Department of Chemistry, University of Zurich.  
 
Column chromatography was performed by using Merck silica gel 60 (63 – 200 µm) with eluents indicated in the 
experimental section. Standard thin-layer chromatography (TLC) for synthesis employed Merck TLC plates silica gel 
60 on an aluminium base with the indicated solvent system. The spots on TLC were visualised either by UV/visible 
light (254 nm) or by staining with KMnO4.  
 
Semi-preparative high-performance liquid chromatography (HPLC) purifications were performed using a Rigol HPLC 
system (Contrec AG, Dietikon, Switzerland) equipped with a C18 reverse-phase column (VP 250/21 Nucleodur C18 
HTec, 21 mm ID x 250 mm, 5μm) using a flow rate of 8 mL min-1 with a linear gradient of solvent A (distilled H2O 
containing 0.1% TFA) and B (MeOH): t = 0-3 min., 60% A; t = 25-30 min., 5% A; t = 33-38 min., 60% A. Electronic 
absorption was measured at 254 nm.  
 
Analytical ultra-high-performance liquid chromatography (UHPLC) experiments were performed using two separate 
Hitachi Chromaster Ultra Rs systems fitted with either a reverse phase VP 250/4 Nucleodur C18 HTec (4 mm ID x 
250 mm, 5μm) column or a reverse phase Acquity UPLC column (BEH C18, 1.7 µm, 2.1 mm ID x 50 mm). One of 
these systems was also connected to a radioactivity detector (FlowStar2 LB 514, Berthold Technologies, Zug, 
Switzerland) equipped with a 20 µL PET cell (MX-20-6, Berthold Technologies) for analysing radiochemical reactions. 
Proteins were analysed by using the same UHPLC system equipped with a size-exclusion column (Enrich SEC 70 
column: 24 mL volume, 10 ± 2 µm particle size, 10 mm ID x 300 mm, Bio-Rad Laboratories, Basel, Switzerland). 
UHPLC using the Acquity column used a flow rate of 0.6 mL min-1 with a linear gradient of solvent A (distilled H2O 
containing 0.1% TFA) and B (acetonitrile): t = 0-0.5 min., 30% A; t = 9.5 min., 0% A; t = 10 min., 0% A. Electronic 
absorption was measured at 254 nm.  
 
Analytical high performance liquid chromatography (HPLC) experiments for photodegradation kinetics were 
performed using a Hitachi Chromaster system equipped with a reverse phase column (Reproshell 100 Dr. Maisch 
C18, 2.8 µm, 75  x 4.6 mm) using a flow rate of 1.5 mL min-1 with a linear gradient of solvent A (distilled H2O 
containing 0.1% HCOOH) and B (acetonitrile): t = 0 min., 95% A; t = 5.8 min., 0% A; t = 6.8 min., 0% A; t = 7.3 min., 
90% A. Electronic absorption was measured at 260 nm.  
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Electronic absorption spectra were recorded using a NanodropTM OneC Microvolume UV-Vis Spectrophotometer 
(ThermoFisher Scientific, supplied by Witec AG, Sursee, Switzerland). Protein concentration was determined in 
accordance with the manufacturers protocol.  
Photochemistry 
Photochemical conjugation experiments were performed in transparent glass vials at the indicated concentrations. 
Stock solutions were prepared in H2O (trastuzumab and DFO-ArN3 [1]). Photochemical reactions were stirred gently 
using a magnetic stir bar. Detail procedures and reaction times are indicated in the experimental section. Irradiations 
used three light sources. For pre-conjugation experiments, a high-powered Rayonet reactor1 (350 nm, 16 x 8 W 
Sylvania BLB-lamps, 10 cm diameter) was used. For kinetic studies and for simultaneous one-pot 
photoradiochemical labelling reactions, portable, high-powered, light-emitting diodes (LEDs at either 365 nm or 395 
nm) were used. The LED intensity was adjusted using a UV-LED controller (Opsytec Dr. Gröbel GmbH, Ettlingen, 
Germany), where 100% corresponded to a power of approximately 263 mW and 355 mW for the 365 nm and 395 nm 
sources, respectively. LED intensity was measured using a S470C Thermal Power Sensor Head, Volume Absorber, 
0.25 - 10.6 µm, 0.1mW - 5W, Ø15 mm. Total irradiance power of the Rayonet reactor was estimated to be 
approximately 92 mW (approximately 300 mW/cm3). Note that calculation of exact power incident to the reaction is 
non-trivial because it depends on the specific geometry of the experimental set-up. The temperature of all 
photochemical conjugation reactions was typically 23 ± 2 oC. Emission spectra of the three light sources are shown in 
Figure S1. The Rayonet reactor had an experimentally measured lmax at 368 nm with full-width at half-maximum 
(FWHM) value of 16.0 nm. The LED (365 nm) had a maximum emission intensity at 364.5 nm (FWHM of 9.1 nm). 
The LED (395 nm) had a maximum emission intensity at 389.9 nm (FWHM of 9.1 nm). 
Figure S1, related to Figure 2.  (A) Emission spectra of the Rayonet reactor (red) and the two LED light sources 
(365 nm, blue; 395 nm, black). (B) Measured power (mW) versus the digitally controlled LED intensity (%). 
 
Radioactivity and radioactive measurements 
All instruments for measuring radioactivity were calibrated and maintained in accordance with previously reported 
routine quality control procedures.2 [89Zr][Zr(C2O4)4]4-(aq.) was obtained as a solution in ~1.0 M oxalic acid from 
PerkinElmer (Boston, MA, manufactured by the BV Cyclotron VU, Amsterdam, The Netherlands) and was used 
without further purification. Radioactive reactions were monitored by using instant thin-layer chromatography (radio-
iTLC). Glass-fibre iTLC plates impregnated with silica-gel (iTLC-SG, Agilent Technologies) were developed in using 
aqueous mobile phases containing either EDTA (50 mM, pH7.1) or DTPA (50 mM, pH7.4) and were analysed on a 
radio-TLC detector (SCAN-RAM, LabLogic Systems Ltd, Sheffield, United Kingdom). Radiochemical conversion 
(RCC) was determined by integrating the data obtained by the radio-TLC plate reader and determining both the 
percentage of radiolabelled product (Rf = 0.0) and ‘free’ 89Zr (Rf = 1.0; present in the analyses as either 
[89Zr]Zr(EDTA) or [89Zr]Zr(DTPA). Integration and data analysis were performed by using the software Laura version 
5.0.4.29 (LabLogic). Appropriate background and decay corrections were applied as necessary. Radiochemical 
purities (RCPs) of labelled protein samples were determined by size-exclusion chromatography (SEC) using two 
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different columns and techniques. The first technique used an automated size-exclusion column (Bio-Rad 
Laboratories, ENrich SEC 70, 10 ± 2 µm, 10 mm ID x 300 mm) connected to a UHPLC device (Hitachi 
ChromasterUltra Rs, VWR International, Leuven, Belgium) equipped with a UV/visible diode array detector 
(absorption measured at 220, 254 and/or 280 nm) as well as a radioactivity detector (FlowStar2 LB 514, Berthold 
Technologies, Zug, Switzerland). Isocratic elution with phosphate buffered saline (PBS, pH7.4) was used. The 
second method used a manual procedure involving size-exclusion column chromatography using a PD-10 desalting 
column (Sephadex G-25 resin, 85-260 µm, 14.5 mm ID x 50 mm, >30 kDa, GE Healthcare). For analytical 
procedures, PD-10 columns were eluted with sterile saline or PBS. A total of 40 x 200 µL fractions were collected up 
to a final elution volume of 8 mL. Note that the loading/dead-volume of the PD-10 columns is precisely 2.50 mL which 
was discarded prior to aliquot collection. For quantification of radioactivity, each fraction was measured on a gamma 
counter (HIDEX Automatic Gamma Counter, Hidex AMG, Turku, Finland) using an energy window between 480 – 
558 keV for 89Zr (511 keV emission) and a counting time of 30 s. Appropriate background and decay corrections were 
applied throughout. PD-10 SEC columns were also used for preparative purification and reformulation of radiolabelled 
products by collecting a fraction of the eluate corresponding to the high molecular weight protein (>30 kDa fraction 
eluted in the range between 0.0 to 1.6 mL as indicated for each experiment). 
Cell culture 
For cell binding assays, the human ovarian cancer cell line SK-OV-3 (HER2/neu-positive, American Type Culture 
Collection [ATCC-HTB-77], Manassas, VA) was used. Cells were cultured at 37 °C in a humidified 5% CO2 
atmosphere in DMEM/F12 (1:1) (Dulbecco’s Modified Eagle Medium, F-12 Nutrient mixture (Ham), ThermoFisher 
Scientific, Schlieren, Switzerland) medium containing [+]-L-glutamine (2.5 mM), supplemented with fetal bovine 
serum (FBS, 10% (v/v), ThermoFisher Scientific) and penicillin/streptomycin (P/S, 1% (v/v) of penicillin 10000 U/mL 
and streptomycin 10 mg/mL). Cells were grown by serial passage and were harvested by using trypsin (0.25%). 
Cell binding assays (immunoreactivity)  
Cell binding assays were performed in accordance with the following general procedure. SK-OV-3 cells were harvested 
using trypsinisation (0.25%) and collected by centrifugation (2000 RPM, 10 min.). The medium was removed and the cell 
pellet was resuspended in complete medium containing NaN3 (0.1% w/w). Subsequently, a two-fold serial dilution of the 
number of cells was performed. Cell stocks ranging from 5 x 106 cells to 15 x 104 cells were prepared in six microcentrifuge 
tubes with each tube containing a final volume of 0.5 mL cell suspension. One of the four prepared dilution series was 
incubated with a 6000-fold molar excess of non-radiolabelled trastuzumab (98.9 µg, 0.682 nmol) with respect to 
[89Zr]ZrDFO-azepin-trastuzumab for 1 h prior to the addition of the radiotracer as a control for accessing non-specific 
binding. [89Zr]ZrDFO-azepin-trastuzumab formulated in sterile PBS was prepared in accordance with the procedures 
described below. For cell binding assays, [89Zr]ZrDFO-azepin-trastuzumab (6.8 µL, 2.22 µg of protein, 0.0153 nmol, 200 
kBq) was diluted with PBS (13.5 mL). A constant amount of diluted [89Zr]ZrDFO-azepin-trastuzumab was added to each 
Eppendorf tube containing the cell suspensions (100 µL per sample, containing ~0.0164 µg of protein, 1.1 x 10-13 mol, ~1.5 
kBq). Cells were subsequently incubated while keeping them in suspension by shaking. After 1 h at 37 °C, the Eppendorf 
tubes were placed on ice and the cells were pelleted by centrifugation (4 °C, 3000 RPM, 5 min.). The medium was discarded 
and the pellets were washed with ice cold PBS (2 x 0.5 mL, centrifugation at 4 °C, 3000 RPM, 5 min.). Important: Cells were 
kept on ice throughout the entire washing procedure to minimise the rate of dissociation. Subsequently, the radioactivity in 
each pellet was quantified with the gamma counter. Standard samples of the radiotracer (3 x 100 µL) were kept separately 
and served as a reference of initial radioactivity added to the cells. 
 
The immunoreactive fraction of [89Zr]ZrDFO-azepin-trastuzumab was estimated by plotting standard saturation binding 
curves. In addition, the immunoreactive fraction was also estimated by using procedures reported by Lindmo et al.4 Linear 
regression analysis of a plot of (total/bound) activity versus (1/[number of cells]) yielded the immunoreactive fraction 
calculated as 1/y-intercept. 
Stability studies 
The stability of [89Zr]ZrDFO-azepin-trastuzumab with respect to change in radiochemical purity due to loss of 
radioactivity from the protein fraction was investigated in vitro by incubation in human serum. Aliquots of [89Zr]ZrDFO-
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azepin-trastuzumab (250 µL, 81.5 µg, 0.54 nmol, 6.59 MBq, Am ~12.1 MBq/nmol) were added to human serum (400 
µL) giving a total reaction volume of 650 µL. Solutions were incubated at 37 oC and SEC-UHPLC measurements 
recorded at the specified time points up to 45 h. The stability was monitored by quantifying the radioactivity 
associated with intact [89Zr]ZrDFO-azepin-trastuzumab from integration of the decay corrected SEC-UHPLC 
radioactive chromatograms. 
Animals and xenograft models 
All experiments involving mice were conducted in accordance with an animal experimentation licence approved by 
the Zurich Canton Veterinary Office, Switzerland (Jason P. Holland). Experimental procedures also complied with 
guidelines issued in the Guide for the Care and Use of Laboratory Animals.5 Female athymic nude mice 
(Crl:NU(NCr)-Foxn1nu, 20 – 25 g, 6 – 8 weeks old) were obtained from Charles River Laboratories Inc. (Freiburg im 
Breisgau, Germany), and were allowed to acclimatise at the University of Zurich Laboratory of Animal Science 
vivarium for at least 1 week prior to implanting tumour cells. Mice were provided with food and water ad libitum. 
Tumours were induced on the right shoulder or flank by sub-cutaneous (s.c.) injection of approx. 2.9 × 106 cells. The 
cells were injected in a 200 μL suspension of a 1:1 v/v mixture of PBS and reconstituted basement membrane 
(Corning® Matrigel® Basement Membrane Matrix, obtained from VWR International).6 Tumours developed after a 
period of between 3 – 6 weeks. Tumour volume (V / mm3) was estimated by external Vernier caliper measurements 
of the longest axis, a / mm, and the axis perpendicular to the longest axis, b / mm. The tumours were assumed to be 
spheroidal and the volume was calculated in accordance with Equation S1.  
 
      (Equation S1) 
Small-animal PET imaging 
All mice injected with cancer cells developed tumours and the average volume of the SK-OV-3 tumours was 196 ± 74 
mm3 (n = 12 mice). Mice were randomised before the study. The tail of each mouse was warmed gently using a warm 
water bath immediately before administering [89Zr]ZrDFO-azepin-trastuzumab (normal group n = 6 mice / group: 1.02 
– 1.09 MBq, [27.5 – 29.6 µCi], 13.75 µg of protein, in 250 µL sterile PBS) via intravenous (i.v.) tail-vein injection (t = 0 
h). Competitive inhibition studies (blocking group: n = 6 mice / group, 1.16 – 1.22 MBq, [31.4 – 33.0 µCi], 1.4 mg of 
total protein, in 250 µL sterile PBS) were also performed to investigate the specificity and biological activity of the 
radiotracer in vivo. Note that one mouse in the normal group was excluded from the experiment and data analysis 
due to an aberrant pharmacokinetic profile in which the radiolabelled antibody was rapidly extracted from circulation 
and accumulated almost entirely in the liver and spleen within ~8 h post-administration. Further details on this 
phenomenon will be reported elsewhere. Full details on radioactive dose preparation are given below. Briefly, to 
prepare the blocking dose, an aliquot of non-radiolabelled trastuzumab (stock solution containing 57.7 mg/mL of 
protein in sterile saline) was added to the [89Zr]ZrDFO-azepin-trastuzumab formulation (~98-times more protein 
compared to the normal group). 
 
PET imaging experiments were conducted on a Genesis G4 PET/X-ray scanner (Sofie Biosciences, Culver City, 
CA).7 Approximately 5 minutes prior to recording each PET image, mice were anesthetised by inhalation of between 
2 – 4% isoflurane (AttaneTM, Piramal Enterprises Ltd, India, supplied by Provet AG, Lyssach, Switzerland)/oxygen 
gas mixture and placed on the scanner bed in the prone position. PET images were recorded at various time-points 
between 2 h and 94 h post-administration of the radiotracer. During image acquisition, the respiration rate of the 
animal was monitored via live video feed and anaesthesia was maintained by an experience animal experimenter by 
controlling the isoflurane dose between 1.5 – 2.0%. List-mode data were acquired for 10 min. using a γ-ray energy 
window of 150–650 keV, and a coincidence timing window of 20 ns. Images were reconstructed by iterative ordered 
subset maximum expectation (OSEM; 60 iterations) protocols. The reported reconstructed spatial resolution is 2.4 µL 
at the centre of the field-of-view (FOV). Image data were normalised to correct for non-uniformity of response of the 
PET, attenuation, random events, dead-time count losses, positron branching ratio, and physical decay to the time of 
injection, but no scatter or partial-volume averaging correction was applied. An empirically determined system 
calibration factor (in units of [Bq/voxel]/[MBq/g] or [Bq/cm3]/[MBq/g]) for mice was used to convert voxel count rates to 
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activity concentrations. The resulting image data were normalised to the administered activity to parameterise images 
in terms of %ID/cm3 (equivalent to units of %ID/g assuming a tissue density of unity). Images were analysed by using 
VivoQuantTM 3.5 patch 2 software (InviCRO, Boston, MA). For image quantification and measurements of time-
activity curves (TACs), 3-dimensional volumes-of-interest (VOIs) were drawn manually to determine the maximum 
and mean accumulation of radioactivity (in units of %ID/cm3 and decay corrected to the time of injection) in various 
tissues. Where appropriate, data were also converted into mean standardised uptake values (SUVmean). 
Biodistribution studies 
Biodistribution studies were conducted after the final imaging time point to evaluate the radiotracer uptake in tumour-
bearing mice. Animals (n = 6 mice / group) were anaesthetised individually by isoflurane and euthanised by isoflurane 
asphyxiation followed by terminal exsanguination. Note: one mouse was excluded from the analysis of the data from 
the normal group (vide supra). A total of 15 tissues (including the tumour) were removed, rinsed in water, dried in air 
for approx. 2 min., weighed and counted on a calibrated gamma counter for accumulation of activity. The mass of 
radiotracer formulation injected into each animal was measured and used to determine the total number of counts per 
minute (cpm) injected into each mouse by comparison to a standard syringe of known activity and mass. Count data 
were background- and decay-corrected, and the tissue uptake for each sample (determined in units of percentage 
injected dose per gram [%ID/g]) was calculated by normalisation to the total amount of activity injected for each 
individual animal. For comparison purposes, data are also presented in terms of SUV.  
Effective half-life, t1/2(eff) 
The effective half-life t1/2(eff) of [89Zr]ZrDFO-azepin-trastuzumab was measured in the same athymic nude mice used 
for small-animal PET imaging and end time point biodistribution. Total internal radioactivity was measured as a 
function of time by using a dose calibrator. 
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Computational details 
All calculations were conducted using density functional theory (DFT) as implemented in the Gaussian16 Revision 
A.03 suite of ab initio quantum chemistry programs. Normal self-consistent field (SCF) and geometry convergence 
criteria were employed throughout. All structures were optimised in the gas phase and in solution phase using a 
polarisable continuum model (PCM). With the exception of calculations on the arylnitrene (ArN) intermediate which 
were calculated using C2v symmetry, all other structures were optimised without using symmetry constraints. 
Solvated phase calculations were implemented using the SCRF keyword with default parameters and selecting water 
as the solvent (dielectric constant, e = 78.3553). Harmonic frequency analysis based on analytical second derivative 
was used to characterise optimised structures as local minima or first order saddle points (transition states) on the 
potential energy surface. Calculations were performed using the unrestricted uB3LYP exchange-correlation 
functionals and the triple-ζ 6-311++G(d,p) basis set by Pople and co-workers. The choice of solvation model reflects 
our standard aqueous phase conditions employed in the photoradiochemical synthesis of [89Zr]ZrDFO-azepin-
trastuzumab. Optimised structures and molecular orbitals were analysed by using Chemcraft (version 1.8, build 
536b). 
 
For closed shell singlet species, the calculations converged to the restricted result. Calculations on the arylnitrene 
species (C2v symmetry) in the open-shell singlet (1A2 state) or triplet (3A2 state) required the unrestricted formalism. 
Ground state geometry optimisations of arylazide (ArN) specifying the singlet state converged to the higher energy 
1A1 state with a (py)2 electronic configuration where both electrons occupied the in-plane py orbital. Checks on the 
stability of the wavefunction confirmed that this state was unstable with respect to both the lower energy open-shell 
1A2 state (px)1(py)1 configuration and also the lower energy 3A2 state. Geometry optimisation of ArN in the triplet state 
was accomplished by specifying the triple state in the root section. Optimisation to the lowest energy open-shell 
singlet 1A2 state required control over the molecular orbital population using the Guess=(always,alter) keyword. The 
initial orbital population guess placed both the alpha and beta electrons in the highest occupied molecular orbitals 
(HOMOs) which had B2 symmetry and corresponding to the in-plane py orbital on the N atom. In both the alpha and 
beta orbital manifolds the lowest unoccupied molecular orbital (LUMO) had B1 symmetry and corresponded to the to 
the out-of-plane px orbital on the N atom. Convergence to the 1A2 state was achieved by switching the orbital 
occupancy from the 24(B2) orbital to the 25(B1) orbital in the beta manifold. Note that spin contamination was 
observed in the optimised 1A2 state calculations with the spin expectation value of <S2> = 1.000 indicating a 50:50 
mixture with a triplet contamination. Therefore, energies of the 1A2 state were estimated using the sum method 
reported by Ziegler et al.3 The structure of the alternative higher energy closed-shell 1A1 singlet state with a (px)2 
electronic configuration was also optimised using a similar control of the orbital populations. 
 
Time-dependent density functional theory (TD-DFT) calculations were performed on the model compound arylazide 
(PhN3). Transition energies and oscillator strengths for electronic excitation to the first 16 excited states (including 
both singlet and triplet states) were calculated by using the unrestricted uB3LYP/6-311++G(d,p) methodology 
incorporating the default PCM in water. No symmetry constraints were used in TD-DFT calculations. The simulated 
TD-DFT electronic absorption spectrum in Figure 4 (main article) was calculated by using a Lorentzian line 
broadening function with a full-width at half maximum (FWHM) value set at 20 nm (implemented in Chemcraft). 
Absolute calculated transition energies were shifted linearly by D = +12 nm to optimise the overlay with the 
experimental spectrum but scaling factors were not used.  
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Table S1, related to Figures 4 and 5. Calculated electronic excitation transition energies and oscillator strengths 
based on the TD-DFT calculation (uB3LYP/6-311++G(d,p)/PCM) of the first 16 excited states (singlets and triplets) of 
the model compound arylazide (PhN3). 
 
 
 
 
 
 
Statistical analysis 
Where appropriate, data were analysed by the unpaired, two-tailed Student’s t-test. Differences at the 95% 
confidence level (P-value <0.05) were considered to be statistically significant.  
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Synthesis and chemical characterisation 
Chemical syntheses were performed in accordance with Scheme 2 (main article). All reactions involving 
photosensitive compounds were performed in the dark. HerceptinTM was generously provided by Genentech (South 
San Francisco, CA) and was initially reconstituted in water. The IgG1 antibody component (trastuzumab) was purified 
from HerceptinTM by spin column centrifugation (4000 RPM, 3 x 15 min., 1 x 20 min.) by using a membrane filter 
(Amicon Ultra-4 mL centrifugal filter, Millipore, 10 kDa MWCO). Briefly, aliquots of HerceptinTM (60 mg) were washed 
with H2O (4 x 4 mL) at room temperature and concentrated before use. After concentration, protein samples were 
removed from the centrifugation filter by rinsing with water (500 µL) and the protein concentration was determined 
using a NanodropTM OneC Microvolume UV-Vis Spectrophotometer. Typically, 25 – 30 mg of protein was obtained 
and samples were aliquoted into Eppendorf tubes and stored at -20 ⁰C for future use. 
Synthesis of desferrioxamine-p-arylazide, DFO-ArN3 (1) 
A solution of 4-azidobenzoic acid (206 mg, 1.26 mmol), HATU (506 mg, 1.33 mmol) and N,N-diisopropylethylamine 
(DIPEA, 130 µL) in dry DMF (8 mL) was stirred at room temperature for 40 min. Then desferrioxamine B mesylate 
(DFO, 407 mg, 0.725 mmol) was added to the mixture along with additional DIPEA (95 µL) and N-methylmorpholine 
(250 µL). After stirring at room temperature for 80 h, the mixture was transferred to a single-necked round bottom 
flask (100 mL) and the solvent was evaporated under reduced pressure (25 mbar). The orange-beige residue was 
washed by sonication with cold acetone (6 x 7 mL, -20 °C) and ice-cold H2O (4 x 7 mL). Note that between each 
washing step, the solid residue was collected by centrifugation and cooled. Washing with acetone the orange colour 
and subsequent lyophilisation gave the crude product DFO-ArN3 (1, 40% yield, 228 mg, 0.291 mmol, estimated 68% 
purity measured by 1H NMR) as a white amorphous powder. A portion of the crude product was purified by semi-
preparative HPLC and after lyophilisation, purified compound 1 was obtained as a white amorphous powder. (Yield 
4%, estimated purity >95% by UHPLC and by 1H NMR). 1H NMR (DMSO-d6; 500 MHz): δ (ppm) 9.64 – 9.59 (3H, m, 
3 x N-OH); 8.44 (1H, t, J = 5.4, NHCOPh); 7.88 (2H, arom. d, J = 8.8); 7.77 (2H, m, 2 x NH); 7.19 (2H, arom. d, J = 
8.8); 3.48 – 3.44 (6H, m, 3 x CONOHCH2); 3.24 – 3.20 (2H, m, PhCONHCH2); 3.00 – 2.98 (4H, m, 2 x 
CH2CONHCH2); 2.57 (4H, t, J = 6.9, 2 x NHCOCH2CH2CONOH); 2.26 (4H, t, J = 7.1, 2 x NHCOCH2CH2CONOH); 
1.96 (3H, s, CH3); 1.54 – 1.49 (8H, m, 4 x CH2, 3 x CONOHCH2CH2CH2CH2CH2NHCO + PhCONHCH2CH2); 1.39 – 
1.35 (4H, m, 2 x CH2CONHCH2CH2); 1.28 – 1.21 (6H, m, 3 x CONOHCH2CH2CH2CH2CH2NHCO). 13C{1H} NMR 
(DMSO-d6; 125.8 MHz): δ (ppm) 172.0, 171.3, 170.1, 165.1 (6 CO); 142.1, 131.3 (2C, arom.); 129.0, 118.8 (4C, 
arom., 4 x CH); 47.1, 46.8 (3C, 3 x CONOHCH2); 39.1 (1C, PhCONHCH2, signal overlaps with solvent signal); 38.4 
(2C, 2 x CH2CONHCH2); 29.9 (2C, 2 x NHCOCH2CH2CONOH); 28.8 (CONOHCH2CH2CH2CH2CH2NHCO + 
PhCONHCH2CH2); 27.6 (2C, 2 x NHCOCH2CH2CONOH); 26.0 (CONOHCH2CH2CH2CH2CH2NHCO + 
PhCONHCH2CH2); 23.6, 23.5 (3C, 3 x CONOHCH2CH2CH2CH2CH2NHCO); 20.4 (1C, CH3). UV/vis (MeOH): lmax 269 
nm (e = 72,400 M-1 cm-1). HR-ESI(+)-MS (MeOH): m/z calc. for [M + Na+] 728.37020, found 728.36983 (100%, D = -
0.51 ppm). tR (RP-UHPLC) = 3.30 min (detection at l = 254 nm). RP-UHPLC method: A flow rate of 0.6 mL min-1 with 
a linear gradient of A (distilled H2O containing 0.1% TFA) and B (acetonitrile): t = 0-0.5 min, 70% A; t = 9.5-10 min, 
0% A. 
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Figure S2, related to Scheme 2. HR-ESI-MS data for DFO-ArN3 (1), m/z [M+Na]+ = 728.36983 (100%). 
 
 
 
Figure S3, related to Scheme 2. Reverse-phase UHPLC chromatogram of compound 1 (l = 254 nm).  
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Figure S4, related to Scheme 2. 1H NMR spectrum (DMSO-d6, 500 MHz) of compound 1. 
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Figure S5, related to Scheme 2. 13C{1H} NMR spectrum (DMSO-d6, 125.8 MHz) of compound 1. 
 
 
 
 
  
15 
 
Figure S6, related to Scheme 2. COSY spectrum (DMSO-d6, 500 MHz) of compound 1. 
 
 
 
 
  
16 
 
Figure S7, related to Scheme 2. HSQC spectrum (DMSO-d6) of compound 1. 
 
Figure S8, related to Scheme 2. (A) Experimental electronic absorption spectrum of DFO-ArN3 (1). (B) Plot of the 
measured molar absorption coefficients of compound 1 at 365 nm (blue) and 395 nm (black). 
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Synthesis of [ZrDFO-ArN3]+ (Zr-1+) 
DFO-ArN3 (1, 0.68 mg, 0.964 µmol) was dissolved in a mixture of H2O (50 µL) and NaOH(aq.) (0.1 M, 30 µL). After 
dissolution of compound 1, a clear, colourless solution was obtained. Then the pH of the mixture was reduced to ~8 – 
9 by the addition HCl(aq.) (0.1 M, 2 x 10 µL). Then an aliquot of ZrCl4(aq.) (112 µL, 6 M Zr4+ ions dissolved in 0.1 M 
HCl(aq.)) was added dropwise. The reaction was monitored by RP-UHPLC and after stirring at room temperature for 
2 h, complete conversion was observed. Presence of desired product Zr-1+ was confirmed by a single peak in 
analytical HPLC that gave the expected mass of molecular ion as the base peak in high-resolution electrospray 
ionisation mass spectrometry (see Figure 1 main article and Figure S9 below). tR (RP-HPLC) = 9.47 min (detection at 
l = 254 nm). RP-HPLC method: A flow rate of 0.7 mL min-1 with a linear gradient of A (distilled H2O containing 0.1% 
TFA) and B (acetonitrile): t = 0 min, 90% A; t = 20 min, 10% A. HR-ESI(+)-MS (MeOH): m/z calc. for [M+] 792.262165, 
found 792.26200 (100%, D = 0.43 ppm). 
Figure S9, related to Figure 1. Reverse-phase HPLC chromatogram of compound Zr-1+ (l = 254 nm). 
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Figure S10, related to Figure 1. HR-ESI-MS data for [ZrDFO-ArN3]+ (Zr-1+), m/z [M+] = 792.26200 (100%). 
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Photochemical reaction kinetics 
DFO-ArN3 (1, 0.31 mg, 0.44 µmol) was dissolved in H2O (266 µL) and NaOH(aq.) (21 µL of a 0.1 M stock solution) in 
a transparent reaction vial equipped with a magnetic stir bar. Immediately before starting the photochemical 
conjugation reactions, the pH of the DFO-ArN3 solution was reduced to ~8 – 9 by the addition of HCl(aq.) (12.6 µL of 
a 0.1 M stock solution). The sample was irradiated directly from above with a sheet of white paper placed between 
the vial and the stirring plate. The reactions (performed in duplicate) were irradiated at the specified LED intensity and 
aliquots (30 µL) were removed at the given time points and analysed by electronic absorption UHPLC. Photochemical 
degradation kinetic data are presented in Figure 2 (main article) and Table S2. 
Table S2, related to Figure 2. Experimental data on the change in the relative concentration of [ZrDFO-ArN3]+ (Zr-
1+) during irradiation at 365 nm with the specified LED intensity. 
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Radiochemistry and photoradiochemistry 
Molar activity of the [89Zr][Zr(C2O4)4]4-(aq.) stock solution 
The molar activity of the 89Zr-oxalate stock solution was measured by isotopic dilution assays. Briefly, a stock solution 
of desferrioxamine B mesylate was prepared in water (3.77 mg, MW = 656.79 g mol-1, 5.74 µmol, 1.0 mL, [DFO] = 
5.74 mM) and was diluted to give a secondary solution (2.87 µM). To microcentrifuge tubes (n = 3) was added H2O 
(90 µL) and an aliquot of the secondary DFO stock solution (10 µL, 0.0287 nmol). Then an aliquot of a neutralised 
[89Zr][Zr(C2O4)4]4-(aq.) stock solution (see below for details on the neutralisation step) was added to each tube 
(~1.637 MBq). Reactions were vortexed and incubated at room temperature for 90 min. to ensure complete reaction 
occurred. At the end of the reaction, aliquots were spotted onto iTLC plates and developed using aqueous mobile 
phase containing DTPA (50 mM, pH7.4) or EDTA (50 mM, pH7.1). Radio-iTLC analysis was used to measure the 
radiochemical conversion (RCC) with the product [89Zr]ZrDFO retained at the baseline (Rf = 0.0) and either 
[89Zr]Zr(EDTA) or [89Zr]Zr(DTPA) eluting at the solvent front (Rf = 1.0). The experimentally measured molar activity of 
the [89Zr][Zr(C2O4)4]4-(aq.) stock solution was Am = 37.0 ± 0.12 MBq/nmol.  
Radiosynthesis and characterisation of [89Zr][ZrDFO-ArN3]+ (89Zr-1+) 
A stock solution of DFO-ArN3 (1, 0.67 mg, 0.950 µmol) was dissolved in H2O (50 µL) and NaOH(aq.) (30 µL of a 0.1 
M stock solution). The pH of the DFO-ArN3 solution was reduced to ~8 – 9 by the addition of HCl(aq.) (2 x 10 µL of a 
0.1 M stock solution). A stock solution of [89Zr][Zr(C2O4)4]4- was prepared by adding 89Zr radioactivity from the source 
(68.7 MBq, 70 µL in ~1.0 M aqueous oxalic acid) to a vial containing water (200 µL). The solution was neutralised and 
made slightly basic by the addition of aliquots of Na2CO3(aq.) (1.0 M stock solution, 55 µL added, final pH ~8.3 – 8.5). 
Caution: Acid neutralisation with Na2CO3 releases CO2(g) and care should be taken to ensure that no radioactivity 
escapes the microcentrifuge tube. After CO2 evolution ceased, an aliquot of the neutralised [89Zr][Zr(C2O4)4]4- solution 
(20 – 40 µL, 4.66 MBq) was added to the reaction microcentrifuge vial containing an aliquot of the DFO-ArN3 stock 
solution (10 µL, 95 nmol, 9.5 mM) and water (50 µL) giving a clear, colourless solution (pH 7 – 8). The reaction was 
vortexed and incubated at room temperature. Reaction progress was monitored by radio-ITLC and complete 
radiochemical conversion to give of 89Zr-1+ (Rf = 0.0) was observed in <10 min. Aliquots of the crude reaction mixture 
were analysed be radioactive HPLC (Figure 1, main text). A single peak was observed in the radioactive trace. The 
identity of the radiolabelled compound 89Zr-1+ was confirmed by co-injection with an authenticated sample of natZr-1+. 
tR (RP-HPLC) = 9.48 min. (detection at l = 220, 254 and 280 nm, Figure 1, main text). RP-HPLC method: A flow rate 
of 0.7 mL min-1 with a linear gradient of A (distilled H2O containing 0.1% TFA) and B (acetonitrile): t = 0 min, 90% A; t 
= 20 min, 10% A.  
Photochemical conjugation 
General procedure for photochemical conjugation: A stock solution of photoactive ligand was prepared by dissolving 
DFO-ArN3 (1, 0.85 mg, 1.21 µmol) in water (50 µL) and NaOH(aq.) (40 µL of a 0.1 M stock solution). Immediately 
before starting the photochemical conjugation reactions, the pH of the DFO-ArN3 solution was reduced to ~9 by the 
addition of HCl(aq.) (2 x 10 µL of a 0.1 M stock solution). Note: DFO-ArN3 (1) is sparingly soluble at high pH but starts 
to precipitate slowly when the pH decreases below ~9. For this reason, photochemical reactions should be initiated 
immediately after adding the HCl and the protein. After adjusting the pH, aliquots of the DFO-ArN3 stock solution 
were added to clear 2 mL glass vials equipped with small magnetic stirring bars and containing an aqueous solution 
of trastuzumab (120 µL, 2.76 mg, 1.84 x 10-8 mol, stock protein concentration = 23.0 mg/mL) and a variable amount 
of water (constant total reaction volume = 200 µL). The chelate-to-mAb ratio was varied used 5.3-fold (9 µL), 10.7-
fold (18 µL) or 26.4-fold (45 µL) excess of DFO-ArN3 stock solution. The final pH of the solutions was 8-8.5. The 
reaction mixture was then irradiated for 25 min. using the Rayonet reactor. The irradiated crude mixture was then 
purified by a three-step procedure. First, the mixture was taken in a 30 kDa MWCO membrane centrifugal filter 
(Amicon Ultra-4 mL centrifugal filter, Millipore,), concentrated and washed with PBS (2 x 4 mL) using centrifugation 
(4000 RPM, ~15 min). Then the mixture was purified using a preparative PD-10-SEC column (eluted with PBS, 
collecting the 0.0 – 1.6 mL fraction immediately after discarding the 2.5 mL column dead volume). In the last step, the 
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fraction from PD-10-SEC was taken in a new 30 kDa MWCO membrane centrifugal filter, washed and concentrated 
using PBS (2 x 4 mL) followed by water (2 x 4 mL) as described in first step. The purified protein was removed from 
the spin column filter in a final volume of ~320 µL water. Protein concentration was measured using the Nanodrop. 
Stock solutions of DFO-azepin-trastuzumab were aliquoted and stored at -20 oC. 
89Zr-radiolabelling of DFO-azepin-trastuzumab 
For animal experiments, the radiochemical synthesis of [89Zr]ZrDFO-azepin-trastuzumab was scaled up using a 
sample of DFO-azepin-trastuzumab prepared from an initial chelate-to-antibody ratio of 26.4-to-1 in the 
photochemical conjugation reaction. To a microcentrifuge tube was added water (100 µL) and [89Zr][Zr(C2O4)4]4-(aq.) 
stock solution (70 µL, 88.66 MBq). The oxalic acid was neutralised and made slightly basic by the addition of aliquots 
of Na2CO3(aq.) (~1.0 M, 55 µL, final pH8.1 – 8.3). Caution: Acid neutralisation with Na2CO3 releases CO2(g) and care 
should be taken to ensure that no radioactivity escapes the microcentrifuge tube. After CO2 evolution ceased, an 
aliquot of photochemically conjugated DFO-azepin-trastuzumab (125 µL, 8.0 mg/mL, mass = 1.0 mg of protein, 6.67 
nmol) produced using an initial chelate-to-mAb ratio of 26.4-to-1 was added to the neutralised solution of 
[89Zr][Zr(C2O4)4]4-(aq.). The pH decreased slightly to 6.6 and was readjusted to pH7.4 – 7.7 by the addition of 
Na2CO3(aq.) (~1.0 M, 4 µL). The reaction was mixed gently and then incubated at room temperature for 1 h. The 
reaction was monitored by radio-iTLC. Control reactions performed in the absence of antibody showed complete 
formation of [89Zr]Zr(EDTA) under the conditions used to develop the iTLC plates with no activity retained at the 
baseline (Rf = 0.0). The reaction showed a RCC >95% after the 15 minutes but a slight improvement in RCC 
occurred by 40 min. (RCC >98%), which remained the same by 60 min. After 1 h, the reaction was quenched by the 
addition of a small aliquot of EDTA (5 µL, 50 mM, pH7.4) and incubating for a further 5 min. An aliquot of the crude 
mixture was retained for further analysis and then the major fraction (250 µL) was purified by preparative PD-10-SEC 
eluting with sterile PBS. All crude and purified mixtures were analysed by radio-iTLC, analytical PD-10-SEC and 
SEC-UHPLC. 
 
The radiochemical purity (RCP) of the crude sample of [89Zr]ZrDFO-azepin-trastuzumab was determined by analytical 
PD-10-SEC (>98%) as well as SEC-HPLC (>98%). Purification and formulation [89Zr]ZrDFO-azepin-trastuzumab 
(pH7.4) was completed in <5 min. with a decay corrected radiochemical yield (RCY) of >99%, and a final activity 
concentration of 29.67 MBq/mL. After preparative PD-10-SEC (collecting the 0.0 – 1.8 mL fraction) the RCP was to 
>99.5% (measured by analytical PD-10-SEC) and >98% (measured by SEC-UHPLC).  
 
Aliquots of the final [89Zr]ZrDFO-azepin-trastuzumab product were then prepared for injection in the normal and 
blocking groups of animals (n = 6 mice / group). Briefly, two aliquots of [89Zr]ZrDFO-azepin-trastuzumab (350 µL, 
~10.4 MBq) were added to separate centrifuge tubes. For the normal group dose, the activity was diluted with sterile 
PBS (1.65 mL) giving a final volume of 2.0 mL. For the blocking group, the activity was diluted with sterile PBS (1.511 
mL) and then an aliquot of non-radiolabelled trastuzumab (stock protein concentration = 57.7 mg/mL, 0.139 mL, 8.0 
mg) was added and the solution mixed gently. A total of 7 syringes (250 µL/each) were drawn for both the normal and 
blocking formulations. The seventh syringe was used as a standard for accurate quantification of the biodistribution 
data (vide supra). In addition, aliquots of the normal and blocking formulations were retained and the protein 
concentration was re-measured using the Nanodrop. The measured molar activities (Am / [MBq/nmol] of protein) of 
the injectates (decay-corrected to the point of final formulation) were then calculated as 13.7 MBq/nmol for the normal 
doses and 0.14 MBq/nmol for the blocking doses. The blocking dose contained ~98-fold higher concentration of mAb 
than the normal dose. 
Chelate number estimation 
The number of chemically accessible chelates per antibody produced after photochemically conjugating trastuzumab 
with different initial chelate-to-antibody ratios were estimated by radiolabelling the DFO-azepin-trastuzumab samples 
using an excess of [89Zr][Zr(C2O4)4]4-(aq.), ensuring that the RCC was < 100%. Samples of the crude radiolabelling 
reactions forming [89Zr]ZrDFO-azepin-trastuzumab were analysed by radio-ITLC eluting with EDTA. The fraction of 
89Zr radioactivity retained at the baseline (Rf = 0.0) and at the solvent front (Rf = 1.0, [89Zr]ZrEDTA) was determined 
by integration after appropriate background corrections. Radio-ITLC data for the reaction using the 26.4-fold initial 
chelate-to-mAb ratio is shown in Figure 7A and a plot of the RCC / % versus time for reactions using different initial 
chelate-to-mAb ratios is presented in Figure 7B. Equivalent radio-ITLC data for reactions using 5.3-fold and 10-7-fold 
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initial chelate-to-mAb ratios are given in Figure S11A and S11B. After allowing sufficient time for saturation of the 
accessible chelates (180 min.), the final RCC was used to estimate the number of accessible chelates per antibody 
using the measured (decay corrected) molar activity of [89Zr][Zr(C2O4)4]4- and the known number of moles of antibody 
added to each reaction. Note that it was assumed that Zr4+ ions form a 1:1 stoichiometric complex with DFO (Figure 
S11C). The measured accessible chelate-to-mAb ratios were 0.27, 0.55 and 0.85 for DFO-azepin-trastuzumab 
samples prepared at initial chelate-to-mAb ratios of 5.3, 10.7 and 26.4, respectively. Linear regression analysis 
indicated that the quantum yield for photochemical coupling of compound 1 with trastuzumab was ~0.035. The 
relatively low efficiency is likely due to intramolecular reactions between the activated nitrene, benzazirine or 
ketenimines intermediates are nucleophilic groups (like hydroxamate anions) in the structure of DFO. See the main 
text for further discussions about the quantum yield and photochemical conjugation efficiency using 89Zr-1+. 
Figure S11, related to Figure 7. Radio-ITLC data showing the change in radiochemical conversion versus time for 
the radiosynthesis of [89Zr]ZrDFO-azepin-trastuzumab using pre-photochemically conjugated DFO-azepin-
trastuzumab samples prepared with an initial chelate-to-mAb ratio of (A) 5.3-fold, and (B) 10.7-fold. (C) Plot of the 
experimentally determined accessible chelate-to-mAb ratio versus the initial chelate-to-mAb ratio used in the 
photochemical conjugation step. 
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PET imaging 
Figure S12, related to Figure 9. Temporal [89Zr]ZrDFO-azepin-trastuzumab (normal group) PET images recorded a 
mouse bearing SK-OV-3 tumours on the right flank. T = tumour, H = heart, L = liver, Sp = spleen. 
 
 
 
Figure S13, related to Figure 9. Temporal [89Zr]ZrDFO-azepin-trastuzumab (blocking group) PET images recorded 
a mouse bearing SK-OV-3 tumours on the right flank. T = tumour, H = heart, L = liver, Sp = spleen. 
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Figure S14, related to Figure 10. Time-activity bar chart showing the activity associated with different tissues 
(volumes-of-interest, VOI) versus time. Data presented are based on quantification of the PET images in units of 
SUVmean. 
 
Note: Results of the Student’s t-test analysis comparing the group of normal animals (coloured bars, n = 5) with the 
blocking group (n = 6) are indicated with an asterisk. (**) P-value < 0.01. 
 
Measured effective half-life of [89Zr]ZrDFO-azepin-trastuzumab in vivo 
Figure S15, related to Figures 9 and 10. Plot of the measured activity retained in each mouse versus time.  
 
 
 
Note: mouse number 4 (M4) was excluded from the normal group. 
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Biodistribution data 
Figure S16, related to Figure 11 and Table 1. Bar chart showing ex vivo biodistribution data (%ID/g) for the uptake 
of [89Zr]ZrDFO-azepin-trastuzumab in mice bearing SK-OV-3 tumours. Data were recorded after the final imaging 
time point at 94 h post-injection. (***) Student’s t-test P-value < 0.001. 
 
 
 
Figure S17, related to Figure 11 and Table 1. Bar chart showing ex vivo biodistribution data (SUV) for the uptake of 
[89Zr]ZrDFO-azepin-trastuzumab in mice bearing SK-OV-3 tumours. Data were recorded after the final imaging time 
point at 94 h post-injection. (***) Student’s t-test P-value < 0.001. 
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Figure S18, related to Figure 11 and Table 1. Bar chart showing tumour-to-tissue contrast ratio calculated from the 
ex vivo biodistribution data (in units of %ID/g) for the uptake of [89Zr]ZrDFO-azepin-trastuzumab in mice bearing SK-
OV-3 tumours. 
 
 
 
Figure S19, related to Figures 9, 10 and 11, and Table 1. Maximum intensity projection (MIP) images showing the 
temporal distribution of [89Zr]ZrDFO-azepin-trastuzumab recorded in normal (top) and blocking (bottom) mice bearing 
SK-OV-3 tumours on the right flank. T = tumour, H = heart, L = liver, Sp = spleen. 
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Figure S20, related to Figure 11 and Table 1. Bar chart showing a comparison between the measured tumour-to-
tissue contrast ratios calculated from the ex vivo biodistribution data (in units of %ID/g) for the uptake of [89Zr]ZrDFO-
azepin-trastuzumab in mice bearing SK-OV-3 tumours, and previously reported biodistribution data on the uptake of 
[89Zr]ZrDFO-Nsucc-trastuzumab in mice bearing BT-474 tumours.8 
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Simultaneous, one-pot photoradiochemical synthesis of [89Zr]ZrDFO-azepin-trastuzumab 
Simultaneous, one-pot photochemical conjugation and radiolabelling reactions were performed in accordance with 
the following general procedure. A stock solution of DFO-ArN3 (1, 0.68 mg, 0.964 µmol) was dissolved in H2O (50 µL) 
and NaOH(aq.) (30 µL of a 0.1 M stock solution). The pH of the DFO-ArN3 solution was reduced to ~8 – 9 by the 
addition of HCl(aq.) (2 x 10 µL of a 0.1 M stock solution). Different reactions and control were performed at the same 
time using the same stock solutions. Details are given in Table S3 below. Details for reaction 1 are given here. To a 
transparent glass vial containing water (50 µL) was added an aliquot of pre-purified trastuzumab stock solution (stock 
concentration = 23.0 mg/mL, 50 µL added, 1.15 mg of protein, 7.69 nmol), an aliquot of the DFO-ArN3 stock solution 
(1, 23 µL, 0.222 µmol, ~28.9-fold excess) and an aliquot of pre-neutralised [89Zr][Zr(C2O4)4]4-(aq.) stock solution (50 
µL, 4.2 MBq). Note: see the radiochemistry sections above for details about neutralisation of oxalic acid in the 89Zr 
stock solution. The total reaction volume was kept constant at 150 µL for all reactions. Reactions were stirred and 
irradiated at room temperature for 10 min. at the specified LED wavelength (100% power). Reactions were then 
quenched by the addition of DTPA (10 µL, 50 mM) and aliquots of the crude reaction mixtures were analysed by 
using radio-ITLC, analytical PD-10-SEC and SEC-UHPLC. Data are presented in Figure 12 (main article). For 
reaction 1, an aliquot of the crude, quenched mixture was also purified by preparative PD-10-SEC and spin column 
centrifugation. After isolation of purified [89Zr]ZrDFO-azepin-trastuzumab by preparative PD-10-SEC (collecting the 
0.0 – 2.0 mL high molecular weight fraction using sterile PBS as an eluent) the decay corrected radiochemical yield 
was ~76% and the estimated lower limit (assuming no protein losses) of the molar activity was 0.41 MBq/nmol of 
protein. Aliquots of the purified sample of reaction 1 were then concentrated and analysed by analytical PD-10-SEC 
and SEC-UHPLC. 
Table S3, related to Figure 12. Experimental data on the conditions used in the simultaneous photoradiolabelling 
reactions for the synthesis of [89Zr]ZrDFO-azepin-trastuzumab. 
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